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Abstract: Breast cancer (BC) is the second most common cancer among women. Research shows many women with BC experience anxiety, depression,
and stress (ADS). Epigenetics has recently emerged as a potential mechanism for the development of depression.1 Although there are growing numbers
of research studies indicating that epigenetic changes are associated with ADS, there is currently no evidence that this association is present in women
with BC. The goal of this study was to identify high-throughput methylation sites (CpG sites) that are associated with three psychoneurological symptoms
(ADS) in women with BC. Traditionally, univariate models have been used to examine the relationship between methylation sites and each psychoneurological symptom; nevertheless, ADS can be treated as a cluster of related symptoms and included together in a multivariate linear model. Hence, an
overarching goal of this study is to compare and contrast univariate and multivariate models when identifying methylation sites associated with ADS in
women with BC. When fitting separate linear regression models for each ADS scale, 3 among 285,173 CpG sites tested were significantly associated with
depression. Two significant CpG sites are located on their respective genes FAM101A and FOXJ1, and the third site cannot be mapped to any known gene
at this time. In contrast, the multivariate models identified 8,535 ADS-related CpG sites. In conclusion, when analyzing correlated psychoneurological
symptom outcomes, multivariate models are more powerful and thus are recommended.
Keywords: breast cancer, mixed model, methylation, stress, anxiety, depression
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Introduction

Breast Cancer (BC) is the second most common cancer among
women. Research shows that many women with BC experience major depression and generalized anxiety disorder.2 Significantly higher incidences of post-traumatic stress disorder
and higher scores on emotional distress were also observed
in women with breast cancer.3 One well-studied biological
mechanism leading to anxiety, depression, and stress (ADS)
is cytokine-induced behavioral changes in sick individuals.4
There are both clinical and experimental evidence indicating that activation of the brain cytokine system is related to
depression.4 Cytokine activation not only relates to depression
but also to cancer development.4 Lyon et al have shown that
many groups of cytokines were elevated in women with BC.5
Another biological change (other than cytokine activation) that has recently emerged as a potential mechanism for the
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development of depression is epigenetics.1 DNA methylation
can prevent enzymes from binding to the promoter region of a
gene and thereby cause up- or down-regulation of DNA transcription,1 with these effects potentially being present for sites
throughout the genome. An alternative means for altering the
expression of genes is through position effects for genes localized near the telomere (the ends of the chromosomes).6,7 As
telomeres shorten, the reduction of heterochromatin could
result in alterations in chromatin conformation, which leads
to changes in the expression of nearby genes.8,9 Furthermore, shortening of telomeres is associated with increased
levels of chromosomal instability, which, in turn, could lead
to alterations in gene expression. It has been shown that
accelerated telomere shortening is associated with psychosocial
stress,10 and that hypermethylation is associated with panic
disorder.11 Although there are growing numbers of research
Cancer Informatics 2015:14(S2)
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studies indicating that epigenetic changes are associated with
ADS, there is currently no evidence that this association is
present in women with BC.
The goal of this study is to identify methylation patterns
that are associated with three psychoneurological symptoms,
ADS, in women with BC. A commonly used and well-validated
questionnaire to measure anxiety and depression is the Hospital Anxiety and Depression Scale (HADS),12 and a widely
used and well-validated instrument for measuring perceived
stress is the Perceived Stress Scale (PSS).13 Genome-wide
methylation was assessed using the high-throughput Illumina
Human Methylation 450K assay.
Traditionally, univariate models have been used to
examine the relationship between molecular features and
each outcome variable (ADS); nevertheless, analyzing multiple outcome variables globally has become more frequent in
many fields of biomedical research.14 In fact, this approach
is especially helpful for evaluating traits that appear related.
For example, evidence that stress is related to depression
and anxiety in women with BC comes from the results of
a study by Varni et al, who found that higher levels of perceived stress were associated with increased depression and
anxiety among survivors of childhood cancer.15 Therefore,
instead of fitting separate univariate models to each psychoneurological symptom, ADS can be treated as a cluster
of related symptoms and included together in a multivariate
linear model. Hence, an overarching goal of this study is
to compare and contrast univariate and multivariate models
when identifying molecular features associated with ADS
in women with BC.

Methods

Study design. The study included 73 women with BC
in stage I (n = 21), II (n = 44), or III (n = 8). This research
was approved by the Institutional Review Board at Virginia
Commonwealth University (VCU IRB #HM 13194) and
complied with the principles of the Declaration of Helsinki.
The molecular features and ADS were measured at study
enrollment, prior to their receiving chemotherapy. The severity of depression and anxiety was measured using the HADS,
which is a 14-item questionnaire.12 Among the 14 items, 7
assess anxiety and 7 assess depression. Each item is on a fourlevel ordinal scale, the scale response is calculated such that
the ordinal levels contribute 0–3 points, and the 14 items
within each scale are summed. Using these sums, subjects
may be classified as normal (score ,8), borderline (8–10), or
having clinical anxiety or depression (score .10).16 Although
the scale has an ordered structure, we used the continuous
version of HADS in order to maintain all the information in
the scale and protect power.
Stress was evaluated using a 10-item PSS.17 PSS was
designed to measure the degree to which situations in one’s life
are appraised as stressful.13 Items were designed to monitor how
unpredictable, uncontrollable, and overloaded a respondent’s
140
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life is by asking about the respondent’s feelings and thoughts
during the last month.17 Of the 10 total responses on the
PSS, 6 were negative responses and were given the following
numerical value: never = 0; almost never = 1; sometimes = 2;
fairly often = 3; and very often = 4. The remaining four positive
items in the PSS were scored in a reversed format according
to standard approaches (ie, never = 4; …; very often = 0).18,19
The scores were summed, with the higher total scores of PSS
indicating higher overall stress.17
The Illumina Human Methylation 450K assay was used
to profile human DNA methylation using whole blood from
women diagnosed with breast cancer. The β-values were
defined as the proportion methylated, and were reported for
each CpG site using the minfi Bioconductor package20 in the
R programing environment.21 β-values were plotted against
the percentage of GC content across all samples. Based on the
results, CpG sites with GC content greater than 40% were
filtered out. CpG sites with all β-values over 0.9 or below 0.1
were considered to be constitutively methylated or unmethylated and therefore were excluded from the study.22 Because
single nucleotide polymorphisms (SNPs) may affect the performance of this assay, 23 the CpG sites containing SNPs were
also excluded. After filtering, 285,173 CpG sites remained.
The Illumina Human Methylation 450K Assay uses two types
of probe designs: Infinium I and Infinium II. Peak correction
was used to align the M-values produced by the two types
of probe designs (M-value = log(β/(l – β)).24 In this study,
five subjects had multiple methylation profiles: because these
profiles were highly correlated, the mean methylation levels
were used. After taking the average, the M-values were backtransformed into β-values, which were used in the analysis.
Statistical analysis. The HADS and PSS scales were first
examined using descriptive statistics. To identify the molecular features significantly associated with each of the scales,
a linear regression model was fit to each of the 285,173 CpG
sites. ADS were treated as three separate continuous responses.
The P-values obtained from the linear regression models were
adjusted using the Benjamini–Hochberg (BH) method to control the false discovery rate (FDR). CpG sites with an FDR
less than 0.02 were considered to be significant.
The ADS values were plotted against each other to
produce a scatterplot matrix. Pearson’s correlation among
the three scales was also calculated. Based on the results, it
seemed reasonable to fit a multivariate linear mixed model by
combining all scales. The mixed model included a methylation component, two dummy coded indicators representing
the type of psychoneurological symptom with anxiety as referent level, and the interactions between each indicator and
the methylation component. In addition, the model included
a subject-specific term to account for the correlation among
scales. To illustrate the model with a formula, let Yij represent
the HADS-Anxiety, HADS-Depression, and PSS outcome
for ith subject, where j = l, 2, or 3, respectively. The model can
then be expressed as

Molecular features associated with psychoneurological symptoms

	  

Yij = α + β1xi 1 + β 2 xi 2 + β3 xi 3 + β4 xi 4 + β5 xi 5 + bi + ij

where xi1 and xi2 are indicators representing depression and
stress, xi3 is a methylation component, xi4 is the interaction
between depression and the methylation component, and xi5
is the interaction between stress and the methylation component. The α and the β terms are the intercept and the slope
coefficients, respectively, bi is the random subject effect, and
ij is the sample error. The null hypothesis of no association
between the methylation “signature” and ADS across different psychological disorders was tested by the interaction effect.
The likelihood ratio tests were used to compute P-values,
and the resulting P-values were again adjusted using the BH
method to control the FDR. In order to compare the performance of the multivariate models versus the separate models,
the FDR thresholds used in the multivariate mixed model was
set at 0.02.
All statistical analyses were performed using the R programming environment (version 3.0.2) and the lme4 package.21
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The means and standard deviations for the three scales are
provided in Table 1. The distributions of the three scales are
shown in Figure 1. Although the distribution of HADSDepression is skewed somewhat to the right, based on the
Central Limit Theorem, the mean of HADS-depression will
follow a Gaussian distribution due to the large sample size
(n = 73).25 Pearson’s correlation between anxiety and depression, anxiety and stress, and depression and stress were 0.657,
0.668, and 0.715, respectively, indicating that the three outcome scales were highly correlated; the scatterplot matrix supported this conclusion (Fig. 2).
When fitting separate models for each ADS scale,
among 285,173 CpG sites, the sites with Illumina’s CpG
loci ID (IlmnID) cg14474520, cg17527195, and cg23431989
were significantly associated with depression (Table 2). Further investigation suggested that the methylation level at
sites cg14474520 and cg23431989 were positively associated
with depression (slope coefficients: 104.6 and 70.52). However, at site cg17527195, the methylation level was negatively
associated with depression (slope coefficient: –39.42). The
scatter plots supported this conclusion (Fig. 3). The CpG
site cg14474520 is located on gene FAM101A, and the CpG
site cg23431989 is located on gene FOXJ1. Both FAM101A
and FOXJ1 are cancer-related genes. It has been shown that
down-regulation of FAM101A significantly reduces early
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Figure 1. Density plot of HADS-Anxiety, HADS-Depression, and PSS.

apoptosis in RKO colorectal cancer cells. 26 Recent studies
have suggested that FOXJ1 may be involved in the development of more than one cancer. FOXJ1 can function as a tumor
suppressor in breast cancer. 27 It is also involved in adverse
clinical outcome in ovarian cancers. 28 Chen et al found that
high expression of FOXJ1 is associated with prognosis and
tumor cell proliferation in hepatocellular carcinoma. 27 The
CpG site cg17527195 cannot be mapped to any known genes
at this time.
0
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Table 1. Means and standard deviations of the three response
variables.
Anxiety

Depression

Stress

Mean

8.411

3.658

16.699

SD

3.523

3.220

8.100

Abbreviation: SD, standard deviation.

30

Stress

20
10
0

0

5

10

15

0

10

20

30

40

Figure 2. Scatterplot matrix of HADS-Anxiety, HADS-Depression, and PSS.
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Table 2. Significant CpG sites from the separate models.
IlmnID

Gene name

Location

cg14474520

Family with sequence similarity 101, member A (FAM101A)

12:123346991

cg17527195

Not associated with a gene

13:48301485

cg23431989

Forkhead box J1 (FOXJ1)

17:71649364

Anxiety
Depression

Stress
Note: Locations are defined as chromosome:coordinates and are based on NCBI Build 36.
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Figure 3. Scatterplots of HADS-Depression versus β-values for the three
significant CpG sites.
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among these eight significant sites is cg22749855, which
is located within the SOCS3 gene and is associated with
a gene promoter. SOCS3 is a well-studied oncogene, and
hypermethylation of the SOCS3 promoter is an important
regulatory mechanism for ulcerative colitis-related colorectal cancer.29 Interestingly, ulcerative colitis-related colorectal
cancer is a condition that has also been associated with telomere shortening.30 Using the mouse as a model, researchers
have found that the Socs3 gene is involved in depression in the
mouse brain.31 SOCS3 has also been shown to play a role in
limiting axon regeneration.32 Another interesting CpG site is
cg11334709, which is located within the PIK3CD gene. The
PIK3CD gene is associated with schizophrenia and increased
expression of PIK3CD has been observed with a variation

Frequency

After fitting multivariate models, the P-value histograms support the notion that the multivariate model is more
powerful in identifying significant CpG sites (Fig. 4). In
Figure 4, the observed P-values for the CpG sites from the
multivariate models are skewed more to the right compared
to the three separate models (Fig. 4). The multivariate models
identified 8,535 ADS-related CpG sites (FDR ,0.02). These
8,535 significant CpG sites are located in different regions
including 4,652 open sea (54.5%), 797 CpG islands (9.3%),
622 north shelf (7.3%), 1,099 north shore (12.9%), 518 south
shelf (6%), and 847 south shore (9.9%) sites. The CpG islands
were defined as DNA sequences with greater than 50% GC
bases and more than 60% CpG observed/expected ratio.
The 2-kb sequences upstream and downstream of the CpG
islands were defined as north and south shores, respectively,
and the 2-kb sequences directly upstream and downstream of
the shores were referred to as north or south shelves, respectively. DNA methylation sites in regions other than these are
annotated as “open sea”. 23
Smaller numbers of significant sites can be identified
by decreasing the FDR threshold (FDR = 0.01, number of
significant sites = 6847; FDR = 0.005, number of significant
sites = 4579; FDR = 0.001, number of significant sites = 8).
The information for the eight significant CpG sites when
FDR = 0.001 are shown in Table 3. Of particular interest

0.2

0.4
Stress

50000
20000
0

0.0

0.2

0.4

Figure 4. Histograms of observed P-values from the CpG site
methylation models.
Notes: The top three histograms represent the results from univariate
models (separate models for anxiety, depression, and stress,
respectively). The bottom histogram represents the results from the
multivariate model.
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Table 3. Annotation for eight significant CpG sites from the multivariate models using an FDR threshold of 0.001.
IlmnID

Gene name (symbol)

Related ADS or cancers

Location

cg11334709

PIK3CD antisense RNA1 (PIK3CD-AS1)
Phosphatidylinositol-4,5-bisphosphate
3 kinase, catalytic subunit delta (PIK3CD)

Leukemia34
Colorectal cancer 35
Mantel cell lymphomas36
Hodgkin lymphomas37
Glioblastoma multiforme38
Schizophrenia33

1:9638606

cg08885142

11:68973477

cg03128029

NOP58 ribonucleoprotein (NOP58)

2:202851533

cg23043143

IQ motif containing E (IQCE)

7:2578627

cg11996860

8:102160991

cg06655216

12:88143460

cg22749855

Suppressor of cytokine signaling 3 (SOCS3)

Breast cancer 39
Prostate cancer40
Pancreatic cancer41
Gastric cancer42
Colorectal cancer 29
Depression (mouse model)31

17:73865547

cg16704590

ZNFX1 antisense RNA 1 (ZFAS1)
Small nucleolar RNA, C/D box 12B (SNORD12B)
Small nucleolar RNA, C/D box 12 (SNORD12)

Breast cancer43

20:47330176

Notes: Locations are defined as chromosome:coordinates and are based on NCBI Build 36. Related ADS or cancers are the list of cancers or mental illness we
found that are related to the particular gene where the significant CpG site is located.

of ErB4, a critical neurodevelopmental gene. 33 Figure 5
demonstrates how methylation is differently associated with
the three psychoneurological symptoms at these eight significant CpG sites.
Additionally, we examined the robustness of our results
by analyzing the modified version of HADS (HADS with
items 7, 11, and 12 removed).16 The modified HADS was able
to identify a larger number of significant CpG sites when fitting mixed models using an FDR of 0.02 (10,856 sites). However, the univariate analyses using the modified HADS did
0.2 0.4 0.6 0.8
cg22749855

cg16704590

cg23043143

cg11996860

Anxiety
Depress
Stress

40
30
20
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0
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0.2 0.4 0.6 0.8

Beta

Figure 5. Scatterplots of combined HADS and PSS versus β-values for
the eight significant CpG sites.

not yield any significant CpG sites when the FDR was 0.02.
These results are consistent with the unmodified HADS
results, where we found 8,535 CpG sites significant when
fitting mixed models but none that were significant univariately for anxiety or PSS, and only three that were significant
univariately for depression.

Discussion

Although HADS is commonly used to measure anxiety
and depression, many researchers have argued that HADS
suffers from issues such as lack of consensus on an optimal
cutpoint for detecting anxiety and depression, problematic fit
of some items, and contradictory results regarding optimal
dimensional structures.16 Lambert suggested that, instead of
using the original 14 items, removing items 7, 11, and 12 can
improve the model fit.16 Although in this current study the full
HADS was analyzed to allow for comparisons of results with
other published work, we also analyzed the modified HADS
so that the results could be compared with the analysis of the
original scale. For our methylation data, both the unmodified and modified HADS were able to identify a larger number of significant CpG sites when fitting mixed models using
an FDR of 0.02 (8,535 and 10,856 CpG sites, respectively)
in comparison with the univariate models. In fact, the univariate analyses using the modified HADS did not yield any
significant CpG sites for anxiety, depression, or perceived
stress, which is similar to the unmodified HADS that only
detected three CpG sites, all of which were significantly associated with depression.
The sensitivity study conducted by Illumina stated that
the Human Methylation 450 Assay is reliable when detecting
Cancer Informatics 2015:14(S2)
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a ∆β-value of at least 0.2.23 When comparing two groups, ∆β
is the difference between the mean β-values in the two groups.
Because our outcome was continuous, we defined ∆β as the
range of β-values. Among three significant CpG sites found
by separate models, only cg17527195 had a ∆β greater than
0.2 (0.22); therefore, caution is needed when investigating the
other two sites. Among 8,535 significant CpG sites found by
the multivariate models using the unmodified HADS, 6,847
had a ∆β greater than 0.2 (80%).
The results of our study demonstrate that the multivariate
mixed model is more powerful than fitting separate models.
Using multivariate models, a larger number of CpG sites were
identified as significant. Figure 4 further demonstrated that
the P-value distribution from the multivariate models was
more skewed to the right compared to those from the univariate models, giving rise to more significant findings at a fixed
FDR. Therefore, when analyzing correlated psychoneurological
symptom outcomes, multivariate models are recommended.
In the future, we will additionally have each patient’s
cytokine levels assayed using the BioPlex system, telomere
lengths using a fluorescent in situ hybridization (FISH)-based
assay, and Illumina methylation levels at baseline and at several follow-up time points. The multivariate mixed model
approach will likewise be useful for analyzing longitudinally
collected data.
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